Messages in prescription drug advertising for four chronic diseases, 2003-2016: A content analysis

被引:2
|
作者
Avery, Rosemary J. [5 ]
Niederdeppe, Jeff [2 ,5 ]
Eisenberg, Matthew D. [3 ]
Sood, Neeraj [4 ]
Welch, Brendan [1 ]
Kim, Jungyon Janice [1 ]
机构
[1] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA
[2] Cornell Univ, Dept Commun, Ithaca, NY USA
[3] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA
[4] Univ Southern Calif, Price Sch Publ Policy, Los Angeles, CA 90007 USA
[5] Cornell Univ, Jeb E Brooks Sch Publ Policy, Ithaca, NY USA
基金
美国医疗保健研究与质量局;
关键词
Advertising; Prescription drugs; Diet; Exercise; Content analysis; DIRECT-TO-CONSUMER; LIFE-STYLE; PHYSICAL-ACTIVITY; EXERCISE; DIET; ADVERTISEMENTS; PREVENTION; DEPRESSION; RESPONSES; BEHAVIOR;
D O I
10.1016/j.ypmed.2022.107015
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The objective of this study was to examine the frequency and content of messages related to pharmacological and evidence-based, non-pharmaceutical treatments in direct-to-consumer advertising (DTCA) for prescription drugs treating four chronic diseases in the United States. We used content coding to identify theory-informed categories of messages appearing in a large sample of heart disease, diabetes, depression, and osteoarthritis advertisements, appearing on national and local television between 2003 and 2016 (N = 11,347,070). The data were originally accessed in 2019 and analyzed in 2020-2021. The central message in all pharmaceutical DTCA was drug efficacy. Advertisements for diabetes and heart disease, but not depression or osteoarthritis, contained general (not central) messages about diet and exercise. Advertisements for heart disease primarily portrayed diet and exercise as insufficient for controlling the target health condition. No advertisements in our sample portrayed changes in diet or physical activity as an alternative to drugs. Pharmaceutical DTCA across health conditions employ similar strategies to promote use of the advertised drug but vary widely in whether and how they describe non pharmaceutical treatments that complement or serve as alternatives to medications. Regulators should consider the potential spillover effects of non-pharmaceutical messages in pharmaceutical DTCA when considering future regulatory endeavors.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Medicinal Cannabis on Prescription in The Netherlands: Statistics for 2003-2016
    de Hoop, Bas
    Heerdink, Eibert R.
    Hazekamp, Arno
    [J]. CANNABIS AND CANNABINOID RESEARCH, 2018, 3 (01) : 54 - 55
  • [2] Risky Messages in Alcohol Advertising, 2003-2007: Results From Content Analysis
    Rhoades, Elizabeth
    Jernigan, David H.
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2013, 52 (01) : 116 - 121
  • [3] The Effects of Human Papillomavirus Infection and Vaccination on Cardiovascular Diseases, NHANES 2003-2016
    Liang, Xiaopeng
    Chou, Oscar Hou In
    Cheung, Bernard M. Y.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2023, 136 (03): : 294 - 301.e2
  • [4] Malaria after international travel: a GeoSentinel analysis, 2003-2016
    Angelo, Kristina M.
    Libman, Michael
    Caumes, Eric
    Hamer, Davidson H.
    Kain, Kevin C.
    Leder, Karin
    Grobusch, Martin P.
    Hagmann, Stefan H.
    Kozarsky, Phyllis
    Lalloo, David G.
    Lim, Poh-Lian
    Patimeteeporn, Calvin
    Gautret, Philippe
    Odolini, Silvia
    Chappuis, Francois
    Esposito, Douglas H.
    [J]. MALARIA JOURNAL, 2017, 16
  • [5] Statistical analysis of the 2003-2016 seismicity of Azerbaijan and surrounding areas
    Telesca, Luciano
    Kadirov, Fakhraddin
    Yetirmishli, Gurban
    Safarov, Rafig
    Babayev, Gulam
    Ismaylova, Saida
    [J]. JOURNAL OF SEISMOLOGY, 2017, 21 (06) : 1467 - 1485
  • [6] Trends and characteristics in cough prescription use in ambulatory care settings in the United States: 2003-2016
    Yang, Seonkyeong
    Hincapie-Castillo, Juan M.
    Chang, Ching-Yuan
    Wilson, Debbie L.
    Lo-Ciganic, Jenny
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 253 - 253
  • [7] Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016
    G. Caleb Alexander
    Ken Ogasawara
    Dana Wiegand
    Dora Lin
    Christopher D. Breder
    [J]. Therapeutic Innovation & Regulatory Science, 2019, 53 : 752 - 758
  • [8] CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION, 2003-2016
    Alexander, G. C.
    Ogasawara, K.
    Wiegand, D.
    Lin, D. H.
    Breder, C. D.
    [J]. VALUE IN HEALTH, 2018, 21 : S209 - S209
  • [9] Clinical development of biologics approved by the US Food and Drug Administration, 2003-2016
    Alexander, G. Caleb
    Ogasawara, Ken
    Wiegand, Dana
    Lin, Dora H.
    Breder, Christopher D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 476 - 476
  • [10] Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016
    Alexander, G. Caleb
    Ogasawara, Ken
    Wiegand, Dana
    Lin, Dora
    Breder, Christopher D.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2019, 53 (06) : 752 - 758